SCHEMBL29622170

SCHEMBL29622170

CC(=O)c1ccc(C(=O)N(C)CCNC(=O)OCc2ccccc2)c(O[Si](C(C)C)(C(C)C)C(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BRD4 O60885 1/20 0.39
HTT P42858 1/20 0.39
FOLH1 Q04609 1/20 0.38
PPARG P37231 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
MAPT P10636 1/20 0.37
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.36
SLC1A3 P43003 1/20 0.36
SLC1A1 P43005 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KCNA5 P22460 2/20 0.36
LTB4R Q15722 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29622336 0.84 HTT (0.46) LMNASMN1; SMN2HTTFOLH1L3MBTL1
SCHEMBL25983314 0.74 LMNA (0.56) LMNASMN1; SMN2HTTFOLH1L3MBTL1
SCHEMBL17846625 0.72 LMNA (0.61) LMNASMN1; SMN2HTTFOLH1L3MBTL1
SCHEMBL29622084 0.72 HTT (0.42) LMNASMN1; SMN2HTTFOLH1L3MBTL1
SCHEMBL10827358 0.71 LMNA (0.60) LMNASMN1; SMN2HTTFOLH1L3MBTL1
SCHEMBL14772158 0.69 LMNA (0.65) LMNASMN1; SMN2HTTFOLH1L3MBTL1
SCHEMBL19763216 0.69 LMNA (0.65) LMNASMN1; SMN2HTTFOLH1L3MBTL1
SCHEMBL25962301 0.69 LMNA (0.57) LMNASMN1; SMN2HTTFOLH1L3MBTL1
SCHEMBL7394899 0.68 LMNA (0.60) LMNASMN1; SMN2HTTFOLH1L3MBTL1
SCHEMBL6860035 0.67 SMN1; SMN2 (0.58) LMNASMN1; SMN2HTTL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391765-A1 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-12-07 US disclosed
WO-2022086937-A9 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-02-02 WO disclosed
WO-2022086937-A1 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391765-A1 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL MLLT1, BCR, MCL1 LMNA 1659/4885SMN1; SMN2 3066/4885BRD4 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.